WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

Diabetes Drug Class Linked to Bile Duct and Gallbladder Disease

Diabetes Drug Class Linked to Bile Duct and Gallbladder Disease
Diabetes Drug Class Linked to Bile Duct and Gallbladder Disease

Type 2 Diabetes Drugs

A popular class of drugs used to treat type 2 diabetes may increase the risk of bile duct and gallbladder disease.

The class, GLP-1 (glucagon-like peptide 1) receptor agonists, is given via an injection and includes Byetta (exenatide), Victoza (liraglutide) and Trulicity (dulaglutide).

Health records of more than 1.5 million patients with type 2 diabetes in the United States, the United Kingdom and Canada who were taking an antidiabetic medication were examined in the study, which was published in JAMA Internal Medicine.

GLP-1s were shown to cause a 79% increased risk of developing symptoms associated with bile duct and gallbladder disease compared to those not on any diabetes drug. Put another way, about 3 more patients per 1,000 exhibited symptoms compared to those not taking the medication. The most common adverse effect seen in this population were gallstones.

Another class of diabetes drugs, DPP-4 (dipeptidyl peptidase 4) inhibitors, which are given as a pill and act in a similar way as GLP-1s, did not have the increased risk of bile duct and gallbladder disease. DPP-4s on the market include Januvia (sitagliptin), Onglyza (saxagliptin) and Tradjenta (linagliptin).

However, both GLP-1s and DPP-4s were not associated with an increased risk of acute pancreatitis.

“It’s important that clinicians and patients alike be well informed about possible adverse effects,” Laurent Azoulay, PhD, a senior investigator at the Lady Davis Institute at the Jewish General Hospital in Montreal and the study’s lead author, said in a statement. “As a result of the gallbladder finding, it would be prudent for doctors to warn their patients to seek treatment if they experience symptoms, such as pain in their right side.”

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (1)
0 0 votes
Article Rating
Subscribe
Notify of
guest
1 Comment
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
John_3_16

Based on my research the adverse affects do NOT apply to Ozempic (semaglutide) subcutaneous or Jardiance (empagliflozin) oral. Just say’n. God bless us; one & all.

1
0
Would love your thoughts, please comment.x